For citations:
Borodavina E.V., Isaev P.A., Shurinov A.Yu., Rumyantsev P.O., Krylov V.V., Petrosyan K.M., Kaprin A.D., Ivanov S.A., Podvyaznikov S.O., Romanov I.S., Mudunov A.M., Slashchuk K.Yu., Zhikhorev R.S., Volkonsky M.V., Chagova R.M., Suslova I.R., Khryapa A.I., Lepshokova A.Kh., Fadeeva N.L., Safarova A.R., Kaleykina L.P., Lymar E.V., Chernyakova E.M., Snezhko O.A., Zinkovskaya A.E., Mufazalov F.F., Kuzmina E.S., Druzhinina Yu.V., Musin Sh.I., Mukhitova M.R., Khasanova A.I., Safina S.Z., Kirienko S.L. Efficacy and tolerability of lenvatinib in patients with radioiodine-refractory differentiated thyroid cancer: results of a multicenter observational study in the Russian Federation. Head and Neck Tumors (HNT). 2020;10(1):65-72. (In Russ.) https://doi.org/10.17650/2222-1468-2020-10-1-65-72
Email this article 